Royal Bank of Canada
PBE icon

Royal Bank of Canada’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Royal Bank of Canada’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.7M Buy
59,329
+12,215
+26% +$987K ﹤0.01% 2463
2025
Q4 		$3.87M Sell
47,114
-289
-0.6% -$22.4K ﹤0.01% 2626
2025
Q3 		$3.31M Sell
47,403
-24,474
-34% -$1.65M ﹤0.01% 2996
2025
Q2 		$4.61M Sell
71,877
-3,525
-5% -$218K ﹤0.01% 2634
2025
Q1 		$4.78M Buy
75,402
+13,767
+22% +$926K ﹤0.01% 2294
2024
Q4 		$4.1M Buy
61,635
+4,446
+8% +$307K ﹤0.01% 2469
2024
Q3 		$3.99M Sell
57,189
-1,903
-3% -$132K ﹤0.01% 2455
2024
Q2 		$3.83M Buy
59,092
+1,718
+3% +$109K ﹤0.01% 2396
2024
Q1 		$3.71M Sell
57,374
-36,200
-39% -$2.36M ﹤0.01% 2424
2023
Q4 		$6.16M Buy
93,574
+35,343
+61% +$2.05M ﹤0.01% 2093
2023
Q3 		$3.32M Buy
58,231
+2,164
+4% +$132K ﹤0.01% 2415
2023
Q2 		$3.44M Buy
56,067
+1,449
+3% +$90.4K ﹤0.01% 2391
2023
Q1 		$3.43M Sell
54,618
-2,972
-5% -$192K ﹤0.01% 2387
2022
Q4 		$3.66M Sell
57,590
-1,646
-3% -$104K ﹤0.01% 2378
2022
Q3 		$3.49M Sell
59,236
-9,267
-14% -$571K ﹤0.01% 2366
2022
Q2 		$3.96M Sell
68,503
-5,150
-7% -$297K ﹤0.01% 2305
2022
Q1 		$4.57M Buy
73,653
+5,942
+9% +$363K ﹤0.01% 2335
2021
Q4 		$4.82M Buy
67,711
+10,855
+19% +$786K ﹤0.01% 2402
2021
Q3 		$4.25M Sell
56,856
-4,591
-7% -$350K ﹤0.01% 2423
2021
Q2 		$4.75M Buy
61,447
+426
+0.7% +$31.7K ﹤0.01% 2342
2021
Q1 		$4.5M Sell
61,021
-1,747
-3% -$132K ﹤0.01% 2318
2020
Q4 		$4.4M Sell
62,768
-11,082
-15% -$702K ﹤0.01% 2270
2020
Q3 		$4.18M Sell
73,850
-1,003
-1% -$58.9K ﹤0.01% 2131
2020
Q2 		$4.36M Sell
74,853
-12,131
-14% -$661K ﹤0.01% 2033
2020
Q1 		$4.04M Sell
86,984
-28,191
-24% -$1.47M ﹤0.01% 1959
2019
Q4 		$6.43M Buy
115,175
+18,950
+20% +$988K ﹤0.01% 1970
2019
Q3 		$4.56M Buy
96,225
+4,338
+5% +$222K ﹤0.01% 2150
2019
Q2 		$4.92M Buy
91,887
+32,525
+55% +$1.69M ﹤0.01% 2083
2019
Q1 		$3.28M Sell
59,362
-4,615
-7% -$244K ﹤0.01% 2334
2018
Q4 		$3.01M Buy
63,977
+5,849
+10% +$301K ﹤0.01% 2349
2018
Q3 		$3.46M Sell
58,128
-7,630
-12% -$445K ﹤0.01% 2419
2018
Q2 		$3.6M Sell
65,758
-5,800
-8% -$295K ﹤0.01% 2263
2018
Q1 		$3.52M Sell
71,558
-1,996
-3% -$102K ﹤0.01% 2250
2017
Q4 		$3.47M Buy
73,554
+4,909
+7% +$230K ﹤0.01% 2318
2017
Q3 		$3.43M Buy
68,645
+402
+0.6% +$19.1K ﹤0.01% 2263
2017
Q2 		$3.12M Buy
68,243
+7,823
+13% +$338K ﹤0.01% 2272
2017
Q1 		$2.56M Buy
60,420
+47,599
+371% +$2M ﹤0.01% 2363
2016
Q4 		$497K Sell
12,821
-9,713
-43% -$392K ﹤0.01% 3751
2016
Q3 		$946K Buy
22,534
+9,363
+71% +$384K ﹤0.01% 3148
2016
Q2 		$488K Buy
13,171
+1,529
+13% +$60K ﹤0.01% 3723
2016
Q1 		$445K Sell
11,642
-338
-3% -$13.1K ﹤0.01% 3738
2015
Q4 		$605K Sell
11,980
-16,743
-58% -$827K ﹤0.01% 3589
2015
Q3 		$1.31M Buy
28,723
+856
+3% +$47.8K ﹤0.01% 2618
2015
Q2 		$1.63M Buy
27,867
+6,490
+30% +$371K ﹤0.01% 2488
2015
Q1 		$1.18M Buy
21,377
+12,003
+128% +$649K ﹤0.01% 2716
2014
Q4 		$471K Sell
9,374
-58,622
-86% -$2.87M ﹤0.01% 3626
2014
Q3 		$3.14M Buy
67,996
+3,422
+5% +$154K ﹤0.01% 1963
2014
Q2 		$2.82M Sell
64,574
-3,527
-5% -$143K ﹤0.01% 2040
2014
Q1 		$2.83M Buy
68,101
+32,294
+90% +$1.38M ﹤0.01% 2001
2013
Q4 		$1.33M Buy
35,807
+3,679
+11% +$132K ﹤0.01% 2604
2013
Q3 		$1.13M Buy
32,128
+530
+2% +$17.6K ﹤0.01% 2658
2013
Q2 		$913K Buy
+31,598
New +$898K ﹤0.01% 2651

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Royal Bank of Canada's PBE Position: Q1 2026 in Review

Royal Bank of Canada increased its Invesco Biotechnology & Genome ETF (PBE) stake by 26% in Q1 2026, buying an estimated $987K and bringing the position to 59,329 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2463.

Royal Bank of Canada first reported a position in PBE in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.43M in Q4 2019. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Royal Bank of Canada held 59,329 shares of Invesco Biotechnology & Genome ETF worth $4.7M as of Q1 2026.
  • Royal Bank of Canada bought 12,215 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $987K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2463 holding.
  • Royal Bank of Canada first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Invesco Biotechnology & Genome ETF position peaked at $6.43M in Q4 2019.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.